According to the new research report published by Precedence Research, titled “Immune Checkpoint Inhibitors Market (By Drug Type: CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor; By Disease Indication: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, Others; By End-Users: Hospitals, Specialty Clinics, Academic & Research Institutions) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”, the global immune checkpoint inhibitors market size is expected to be worth around US$ 148.1 billion by 2030 and is poised to record a yearly growth rate of 18.81% from 2022 to 2030. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on immune checkpoint inhibitors market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall immune checkpoint inhibitors market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2281
The study also provides important advancements in organic and inorganic growth strategies in the worldwide immune checkpoint inhibitors market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of immune checkpoint inhibitors market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Immune Checkpoint Inhibitors Market Report Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 37.31 Billion |
| Market Size by 2030 | USD 148.1 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 18.81% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Type, Disease Indication, End-Users, and Geography |
Also read: https://www.uswebwire.com/analgesics-market/
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the immune checkpoint inhibitors market.
Some of the prominent players in the immune checkpoint inhibitors market include are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), GlaxoSmithKline PLC, Roche Holding AG, Incyte Corporation, Novartis AG, F. Hoffmann-La Roche Ltd. (Genentech Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono Inc.), BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd.
Immune Checkpoint Inhibitors Market Segmentations
By Drug Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
By Disease Indication
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Academic & Research Institutions
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, segment, and project the global market size for immune checkpoint inhibitors market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyze the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyze their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyze the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immune Checkpoint Inhibitors Market
5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immune Checkpoint Inhibitors Market, By Drug Type
8.1. Immune Checkpoint Inhibitors Market, by Drug Type, 2022-2030
8.1.1 CTLA-4 Inhibitor
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. PD-1 Inhibitor
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. PD-L1 Inhibitor
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Immune Checkpoint Inhibitors Market, By Disease Indication
9.1. Immune Checkpoint Inhibitors Market, by Disease Indication, 2022-2030
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bladder Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Hodgkin lymphoma
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Immune Checkpoint Inhibitors Market, By End-Users
10.1. Immune Checkpoint Inhibitors Market, by End-Users, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Academic & Research Institutions
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Immune Checkpoint Inhibitors Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
Chapter 12. Company Profiles
12.1. AstraZeneca PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company (ARMO Biosciences.)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Roche Holding AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Incyte Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi, Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA (EMD Serono Inc.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global immune checkpoint inhibitors market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for immune checkpoint inhibitors are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
